Authorship guidelines for EBMT publications

Document Sample
Authorship guidelines for EBMT publications Powered By Docstoc
					                                                      Adopted by the EBMT Board 18.01.2006




                   Authorship guidelines for EBMT publications
This document has been adopted by the EBMT Board 2006-01-18 and should be used to
guide decisions of authorship for future EBMT publications.

Authorship on scientific manuscripts is an important recognition of contributions of
individuals for the benefit of EBMT prospective or retrospective studies. Such a contribution
can include intellectual participation in the preparation of a study or the analysis of data,
reporting patients to the EBMT registries allowing these patient data to be included in
retrospective analyses, or including patients in prospective clinical trials. On the other hand,
many journals have guidelines limiting the number of authors allowed on a publication. This
dichotomy between the need for recognition of the investigator’s contribution(s) and the
journal guidelines might create a conflict of interest. These guidelines are intended to support
WPs in deciding authorship on future scientific publications.

   1. General Guidelines
        a. The EBMT guidelines for retrospective and prospective studies should be
            followed.
        b. The WP Chairperson is responsible for the allocation of WP resources such as
            a data manager and statistical support for the study
        c. The WP chairperson(s) should make the final decision regarding authorship on
            a manuscript based on a WP study.
        d. The WP Chairperson is responsible for the communication with the relevant
            EBMT offices regarding study status.
        e. Principles for authorship regarding a specific study should be decided
            beforehand and documented in the study protocol.
        f. If a joint study is performed with another organization for example the
            CIBMTR, the main authorship positions should be evenly distributed between
            the participating organizations.
        g. Principles for eventual sponsor’s right to review manuscripts before
            submission should be decided beforehand and documented in the study
            protocol.
        h. A sponsor should not under any circumstance have the right to suppress
            publication of data from an EBMT study.
        i. A Writing committee should usually be appointed for the preparation of an
            EBMT study manuscript
        j. All authors should have the opportunity to review an advanced version of the
            manuscript.
        k. All authors should give approval to the final version of the manuscript.
        l. Investigators in prospective studies and contributors to retrospective studies
            should be listed in an appendix to the manuscript.

   2. Retrospective studies
      A writing committee for manuscripts based on prospective studies should include at
      least the following co-authors:
          a. The investigator writing the manuscript.
                                                   Adopted by the EBMT Board 18.01.2006

      b. The study co-ordinator if not the primary author.
      c. The study statistician (if he/she has contributed significantly to conception,
          design, analysis, or interpretation of data).
      d. The subcommittee chair; if appropriate.
      e. Additional members of the WP who contribute significantly to conception,
          design, analysis, or interpretation of data and
      f. The WP chair should normally be the senior author. Exceptions should be
          agreed upon during the planning phase of a study. An example can be when the
          WP chair is changed during an ongoing study when it might be logical that the
          previous chair is the senior author.
   Additional authors can be added in later stages of manuscript preparation including
      g. Representatives of centres contributing significantly to the patient population
          of the study.

3. Prospective studies
   A writing committee for manuscripts based on prospective studies should include at
   least the following co-authors
       a. The investigator coordinating the writing of the manuscript.
       b. Study co-ordinator if not the primary author
       c. The study statistician (if he/she has contributed significantly to conception,
           design, analysis, or interpretation of data).
       d. Other collaborators who have contributed significantly to conception, design,
           analysis or interpretation of data.
       e. Investigators who have provided a substantial proportion of the study
           population for the study.
       f. WP chairman
   Additional authors can be added in later stages of manuscript preparation including
       g. Representatives of centres contributing significantly to the patient population
           of the study.
       h. A representative of a sponsoring pharmaceutical company who has given
           significant input in the conception, design, analysis or interpretation of data for
           the study.

4. Other publications (policy statements, guidelines, annotations etc.)
      a. The WP member writing the manuscript
      b. Other WP members contributing to the policy or guidelines.

5. Acknowledgement of EBMT in manuscripts
      a. All manuscripts originating from the EBMT should include in the main title:
         A study from the European Group for Blood and Marrow Transplantation
         (EBMT).
      b. Manuscripts originating from a WP should at the end of the authorship list
         include: for the xxxx Working Party.

6. The principal data manager(s) of a study should be acknowledged

				
DOCUMENT INFO
Shared By:
Categories:
Tags:
Stats:
views:12
posted:8/1/2011
language:English
pages:2